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ABSTRACT 
They examined 120 elderly patients with chronic heart failure (CHF) against ischemic heart disease (IHD), the 
mean age of the patients was 66.6 ± 6.8 years. The patients were divided into 4 groups. The 1st group consisted of 
the patients who had planned therapy with ß-adrenoblocker (BAB) (metoprolol succinate 12.5-100 mg per day); 
2nd group - angiotensin-converting enzyme (ACE inhibitor) inhibitor (perindopril - 4-8 mg per day); 3rd group - 
combination of BAB and ACE inhibitors; 4th group - BAB, ACEI and the competitive antagonist of aldosterone 
spironolactone with the daily dose of 25-50 mg per day. The effect of therapy on C-reactive protein and cytokines 
(TNF-α, IL-1ß, IL-6) was determined. The content of CRP and TNF-α, IL-1β and IL-6 cytokines in all groups 
decreased in different degrees. It was determined that a significant positive dynamics of TNF-synthesis 
suppression by 67.0% (p˂ 0.0001) was established in the 4th group of patients taking combined therapy with the 
blocker of mineralocorticoid receptors with spironolactone. 
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INTRODUCTION.  
The prevalence of chronic heart failure (CHF) in 
Russian Federation is quite high and amounts at 
least to 3-3.5 million patients with clinically 
significant CHF (III-IV functional class) [1]. 
Modern approaches require take into account the 
pathogenesis of this process for the 
determination of management tactics for the 
patients with CHF as well as to prevent its 
progress among the patients with coronary heart 
disease (CHD) [2]. The appearance of left 
ventricular (LV) dysfunction and its 
transformation from asymptomatic to clinical 
CHF occurs with the participation of neural 
humoral systems: sympathetic adrenal, renin-
angiotensin-aldosterone (RAAS) and immuno-
inflammatory one [3, 4]. In recent years the 
evidence emerged about the parallel existence of 
tissue RAAS in a heart, kidneys, liver, pancreas 
and about the additional synthesis of angiotensin 
fragments, which confirms the role of tissue 
RAAS in growth regulation, proliferation and 
the apoptosis of cardiomyocytes (CMC), as well 
as inflammation increase and, as a consequence, 
the development of fibrosis [5]. 
The strengthening of proinflammatory cytokine 
synthesis is one of the significant components of 
this process. Such cytokines as TNF-α (TNF-α) 
and IL-6 (IL-6) [6,7,8] are confirmed as the 
leading ones in the pathogenesis of systemic 
inflammation induction among the patients with 
CHF. The determination of proinflammatory 
cytokine value and C-reactive protein (CRP) in 
the serum of elderly patients with CHF and 
coronary heart disease and their change under 
the influence of pharmacotherapy deserve a 
separate examination. 
Purpose. To study the effect of spironolactone 
mineralocorticoid receptor antagonist on the 
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level of neurohormones, cytokines and CRP 
among elderly patients with the CHF of 
ischemic genesis. 
 
MATERIALS AND METHODS.  
120 elderly CHF patients were examined on the 
background of ischemic heart disease. 120 men 
(100%) with the average age of 66.6 ± 6.8 years 
had a myocardial infarction more than 4 months 
ago. The New York Heart Association (NYHA) 
used the classification to determine the 
functional class (FC) of CHF using a 6-minute 
walk test. CHF I FC was detected in 37 patients 
(31%), CHF II FC was detected in 43 (36%) 
patients, CHF III FK - in 40 patients (33%). The 
control group consisted of 20 conditionally 
healthy individuals (mean age - 48.9 ± 7.3 
years), who did not have cardiovascular system 
and other organ and system dysfunction at a 
careful clinical laboratory and instrumental 
examination. All patients, depending on the 
treatment, were divided into 4 groups. Group 1 
(n = 35): the planned therapy included ß-
adrenoblockers (BAB) (metoprolol succinate 
12.5-100 mg per day); 2nd group (n = 25) - the 
patients who received the angiotensin-
converting enzyme inhibitor (ACEI) 
(perindopril - 4-8 mg per day); 3rd group (n = 
40) - the patients who took combined treatment 
of BAB and ACEI; Group 4 (n = 20) consisted 
of the patients receiving the combination of 
BAB, ACEI and a competitive antagonist of 
aldosterone (mineralocorticoid receptor 
antagonists) spironolactone in a daily dose of 
25-50 mg per day. 
The study of C-reactive protein, cytokines 
(TNF-α, IL-1ß (IL-1ß), IL-6 (IL-6)) was carried 
out using the special sets for the determination 
of TNF-α, IL-1ß (IL-1ß), IL-6 (IL-6) content 
manufactured by VECTOR-BEST (Russia) for 
CRP by "Eucardio" (USA), guided by the 
manufacturer's instructions. The results of 
cytokines were expressed in pg/ml, CRP - mg/l. 
"Statictica 6.0" software package was used for 
the statistical processing of data. The indicators 
are presented as medians (Me) with interquartile 
range (25% and 75% percentile) using the 
median test. The differences were considered as 
reliable at p <0.05. 
RESULTS.  
The activation of tissue myocardial RAAS 
promotes the development of hypertrophy and 
cardiomyocyte fibrosis [9]. If in the short term 
the activation of the neurohumoral system 
allows to improve the perfusion of organs and 
compensate for circulatory insufficiency, then 
after a certain period the mechanisms begin to 
increase the work of a heart muscle, which is the 
trigger mechanism for the progression of heart 
failure. The activation of cytokine system also 
acts within the same trend. 
The content of CRP and TNF-α, IL-1β and IL-6 
cytokines among elderly patients with CHF on 
the background of IHD under the influence of 
differentiated treatment in all groups decreased 
in different degrees (Table 1). Thus, the 1st 
group of patients during the treatment of BAB, 
showed CRP level decrease by 21.6% 
(p<05.05), and TNF-α by 6.0% and IL-1β by 
2.0% (p> 0.05). In the second group of treated 
ACE inhibitors, the dynamics of CRP content 
after the treatment was reduced by 30.6%, TNF-
α by 24.0%, IL-1β by 10.0% and IL-6 by 21.7%, 
which significantly differed from the baseline 
level. In the blood of patients who received the 
combination therapy of BAB and ACEI against 
standard therapy, the levels of CRP, TNF-α and 
IL-1β also decreased and significantly differed 
from the baseline data. Thus, the content of CRP 
in serum decreased by 43.1% (p<0.001), TNF-α 
by 25.0% (p <0.01), IL-1β by 11% (p <0.05). 
The concentration of IL-6 in this group also 
decreased by 23.3% (p<0.05). In the fourth 
group of patients taking combination therapy, 
ACE inhibitors, BAB and spironolactone, the 
positive dynamics of CRP decrease was 44% 
(р<0.01). The attention is drawn to the decrease 
of TNF-  by 67.0% (p˂ 0.0001) with respect to 
pre-treatment concentration, which is 
statistically significant in relation to all groups 
of drug therapy (p˂ 0.001).  
There is the decrease of IL-1β indicators 
(r˂ 0.05) by 9.0%, but no statistical difference 
with the group of ACEI + BAB is revealed 
(p>0.05). IL-6 decreased by 58% (p˂ 0.001), 
which is 34.7% higher than the group of taking 
IPF with BAB (p˂ 0.01). 
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Summary. Such cytokines as TNF-α, IL-1β, IL-
6 enhancing the expression and detected among 
the patients with CHF represent the class of 
biologically active substances responsible for 
the development of inflammation and the heart 
failure progression [5,10]. Many CHF 
mechanisms may be explained by well-known 
pharmacodynamic effects of proinflammatory 
cytokines, particularly TNF-α, which induces 
other cytokines, playing an important role in 
inflammation, such as IL-1α, IL-1β and IL-6 
[11]. The factors inhibiting apoptosis are 
represented by transforming growth factor-α 
(TRF-α), secreted in immune reactions and 
which has anti-inflammatory properties, but 
enhancing the progression of organ fibrosis 
[4,12]. Experimental and clinical studies 
showed that the potential adverse effects of 
proinflammatory cytokines at CHF are the 
following ones: left ventricular dysfunction, 
pulmonary edema, cardiomyopathy, decreased 
blood flow in legs, cell metabolism 
abnormalities, anorexia and cachexia, impaired 
beta-receptor capture of adenylate cyclase, the 
abnormalities of mitochondrial energy and the 
activation of apathosis gene programs [13,14]. 
Cytokine release, like the release of 
neurohormones, is the biochemical mechanism 
responsible for the development of symptoms 
among the patients with CHF [15,16,17]. 
 
Table 2: Changes of cytokine and CRP content, depending on the type of received therapy (Me (Мен-Мев)) 
 
Indicators 
Metoprolol 
succinate 
Perindopril 
Perindopril, 
metoprolol succinate 
Perindopril, metoprolol 
succinate, spironolactone 
n=35 n=25 n=40 n=20 
CRP, 
mg/l 
 
Before treatment 3.7 (3.5-6.5) 4.9 (3.3-6.3) 5.1 (3.4-7.2) 5.0 (3.3-7.0) 
After treatment 2.9 (1.6-4.1) 3.4 (2.8-4.0) 2.9 (1.9-5.2) 2.8 (1.8-5.1) 
р <0.05 <0.01 <0.01 <0.01 
TNF -α, 
pg/ml 
 
Before treatment 17.0 (7.6-18.7) 18.2 (7.4-26.2) 17.4 (7.2-29.1) 16.9 (7.8-20.7) 
After treatment 15.9 (5.4-22.4) 13.8 (6.6-25.3) 13.1 (8.2-21.6) 5.6 (3.5-7.8) 
р >0.05 <0.01 ˂ 0.01 <0.0001 
IL-1ß, 
pg/ml 
 
Before treatment 183.0 (102.9-255.6) 186.6 (110.2-254.7) 179.8 (120.8-349.3) 180.4 (120.2-305.1) 
After treatment 179.3 (147.3-255.4) 167.9 (130.8-256.3) 160.0 (132.9-250.5) 164.2 (127.3-207.1) 
р ˂ 0.05 <0.05 <0.05 <0.05 
IL-6, 
pg/ml 
 
Before treatment 46.0 (31.9-59.6) 44.7 (35.1-66.2) 44.1 (25.8-69.7) 45.0 (33.8-57.9) 
After treatment 45.1 (16.9-78.1) 35.3 (21.8-68.8) 33.8 (20.7-71.1) 18.9 (15.6-50.6) 
р ˂ 0.05 <0.01 <0.01 <0.001 
In order to interpret the biological activity of 
any cytokine, the concentration of a measured 
cytokine in blood is very important. It 
determines the extent of its involvement, the 
presence or the absence of any circulating 
antagonists, and the concentration of soluble 
and membrane low affinity and high affinity 
receptors in the blood. Circulating soluble 
receptors for cytokines serve as biological 
buffers capable to modulate their cytotoxic 
effects. Cytokines can also enter the 
bloodstream and cause secondary activation of 
an immune system, amplifying the signal to the 
periphery [7.17]. In recent years, it has been 
established that TRP-α and IL-6 determine the 
release of stress-activated cytokines in large 
amounts during a heart failure [18, 19, 20]. In 
our studies, the use of ACE inhibitors 
(perindopril), as well as the combination of 
perindopril and spironolactone, resulted in the 
decrease of pro-inflammatory cytokine release, 
in particular TNF-  and IL-6, among the 
patients with CHF on the background of post-
infarction cardiosclerosis. Apparently, the 
decrease of TNF-  concentration can be 
explained by the effect of spironolactone. 
Clinical and experimental data, as well as the 
results obtained by us, indicate that CHF 
depends on immunoinflammatory cytokine 
activation. The biomarkers of inflammation can 
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be used for diagnostic and prognostic purposes, 
as well as for the monitoring of CHF course 
and the evaluation of therapeutic effects, 
especially among severely injured patients. The 
determination of cytokine expression can be 
one of effective ways for therapeutic 
interventions, including various classes of ACE 
inhibitors and beta-adrenoreceptor blocking 
agents. 
 
CONCLUSIONS 
1. Chronic heart failure during ischemic heart 
disease and postinfarction cardiosclerosis is 
characterized by the activation of 
proinflammatory mechanisms. The effect of 
spironolactone was established on the 
decrease of TNF-  level by 67.0% with 
respect to the concentration before 
treatment. 
2. The determination of cytokine expression 
can be one of the ways to assess the severity 
of disease course and the effectiveness of 
therapeutic interventions, including various 
classes of ACE inhibitors and beta-
adrenoreceptor blocking agents.  
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